AbbVie, Genmab granted EU label expansion for Tepkinly in follicular lymphoma
Seeking Alpha ·
The European Commission has authorized a label expansion for Tepkinly, a blood cancer therapy jointly developed by AbbVie ( ABBV ) and Genmab ( GMAB ) as a first-line option for patients with follicular lymphoma. Accordingly, the bispecific antibody therapy will be available as part
DYAX Investor Sentiment
Bullish (Long) 47% · Bearish (Short) 53%
249 participants
Related News
- Toyota, Honda see China sales decline as EV demand reshapes market
- International Business Machines shares extend rally into a seventh consecutive session
- ExxonMobil Trade Can Pump Out A Premium Or Discounted Shares For The Oil Heavyweight
- Netflix signs deal with digital publishers for homepage content
- Shell rises after stronger-than-expected Q2 trading update; analysts expect upward revisions
- Why Did SpaceX Stock Drop Today?